Titre : Villes

Villes : Questions médicales fréquentes

Termes MeSH sélectionnés :

Visual Field Tests
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Villes : Questions médicales les plus fréquentes", "headline": "Villes : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Villes : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-31", "dateModified": "2025-04-27", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Villes" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Régions géographiques", "url": "https://questionsmedicales.fr/mesh/D005842", "about": { "@type": "MedicalCondition", "name": "Régions géographiques", "code": { "@type": "MedicalCode", "code": "D005842", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Baltimore", "alternateName": "Baltimore", "url": "https://questionsmedicales.fr/mesh/D015142", "about": { "@type": "MedicalCondition", "name": "Baltimore", "code": { "@type": "MedicalCode", "code": "D015142", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.100" } } }, { "@type": "MedicalWebPage", "name": "Pékin", "alternateName": "Beijing", "url": "https://questionsmedicales.fr/mesh/D000068476", "about": { "@type": "MedicalCondition", "name": "Pékin", "code": { "@type": "MedicalCode", "code": "D000068476", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.114" } } }, { "@type": "MedicalWebPage", "name": "Boston", "alternateName": "Boston", "url": "https://questionsmedicales.fr/mesh/D001900", "about": { "@type": "MedicalCondition", "name": "Boston", "code": { "@type": "MedicalCode", "code": "D001900", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.210" } } }, { "@type": "MedicalWebPage", "name": "Chicago", "alternateName": "Chicago", "url": "https://questionsmedicales.fr/mesh/D002641", "about": { "@type": "MedicalCondition", "name": "Chicago", "code": { "@type": "MedicalCode", "code": "D002641", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.305" } } }, { "@type": "MedicalWebPage", "name": "District de Columbia", "alternateName": "District of Columbia", "url": "https://questionsmedicales.fr/mesh/D004219", "about": { "@type": "MedicalCondition", "name": "District de Columbia", "code": { "@type": "MedicalCode", "code": "D004219", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.429" } } }, { "@type": "MedicalWebPage", "name": "Los Angeles", "alternateName": "Los Angeles", "url": "https://questionsmedicales.fr/mesh/D015141", "about": { "@type": "MedicalCondition", "name": "Los Angeles", "code": { "@type": "MedicalCode", "code": "D015141", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.565" } } }, { "@type": "MedicalWebPage", "name": "Nouvelle-Orléans", "alternateName": "New Orleans", "url": "https://questionsmedicales.fr/mesh/D055820", "about": { "@type": "MedicalCondition", "name": "Nouvelle-Orléans", "code": { "@type": "MedicalCode", "code": "D055820", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.697" } } }, { "@type": "MedicalWebPage", "name": "New York (ville)", "alternateName": "New York City", "url": "https://questionsmedicales.fr/mesh/D009519", "about": { "@type": "MedicalCondition", "name": "New York (ville)", "code": { "@type": "MedicalCode", "code": "D009519", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.741" } } }, { "@type": "MedicalWebPage", "name": "Philadelphie", "alternateName": "Philadelphia", "url": "https://questionsmedicales.fr/mesh/D015143", "about": { "@type": "MedicalCondition", "name": "Philadelphie", "code": { "@type": "MedicalCode", "code": "D015143", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.820" } } }, { "@type": "MedicalWebPage", "name": "San Francisco", "alternateName": "San Francisco", "url": "https://questionsmedicales.fr/mesh/D012495", "about": { "@type": "MedicalCondition", "name": "San Francisco", "code": { "@type": "MedicalCode", "code": "D012495", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.875" } } }, { "@type": "MedicalWebPage", "name": "Séoul", "alternateName": "Seoul", "url": "https://questionsmedicales.fr/mesh/D066106", "about": { "@type": "MedicalCondition", "name": "Séoul", "code": { "@type": "MedicalCode", "code": "D066106", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.887" } } }, { "@type": "MedicalWebPage", "name": "Tokyo", "alternateName": "Tokyo", "url": "https://questionsmedicales.fr/mesh/D014041", "about": { "@type": "MedicalCondition", "name": "Tokyo", "code": { "@type": "MedicalCode", "code": "D014041", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "Z01.433.900" } } } ], "about": { "@type": "MedicalCondition", "name": "Villes", "alternateName": "Cities", "code": { "@type": "MedicalCode", "code": "D002947", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Divya Seth", "url": "https://questionsmedicales.fr/author/Divya%20Seth", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, 3950 Beaubien, 4th Floor, Pediatric Specialty Building, Detroit, MI 48201, USA. Electronic address: dseth@dmc.org." } }, { "@type": "Person", "name": "Shweta Saini", "url": "https://questionsmedicales.fr/author/Shweta%20Saini", "affiliation": { "@type": "Organization", "name": "Division of Hospital Medicine, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Pavadee Poowuttikul", "url": "https://questionsmedicales.fr/author/Pavadee%20Poowuttikul", "affiliation": { "@type": "Organization", "name": "Division of Allergy/Immunology, Department of Pediatrics, Children's Hospital of Michigan, Wayne State University School of Medicine, Detroit, MI, USA." } }, { "@type": "Person", "name": "Marc Barthelemy", "url": "https://questionsmedicales.fr/author/Marc%20Barthelemy", "affiliation": { "@type": "Organization", "name": "Université Paris-Saclay, CEA, CNRS, Institut de Physique Théorique, 91191 Gif-sur-Yvette, France." } }, { "@type": "Person", "name": "Sasha Khomenko", "url": "https://questionsmedicales.fr/author/Sasha%20Khomenko", "affiliation": { "@type": "Organization", "name": "Institute for Global Health, Barcelona, Spain; Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "[The ground visual field assessment, using two methods, compared with Goldmann perimetry].", "datePublished": "2022-07-05", "url": "https://questionsmedicales.fr/article/35798620", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jfo.2022.03.018" } }, { "@type": "ScholarlyArticle", "name": "Association Between Longitudinal 10-2 Central Visual Field Change and the Risk of Visual Acuity Loss in Mild-to-Moderate Glaucoma.", "datePublished": "2023-05-10", "url": "https://questionsmedicales.fr/article/37171991", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/IJG.0000000000002236" } }, { "@type": "ScholarlyArticle", "name": "Visual field progression in open-angle glaucoma after refractive corneal ablation surgery.", "datePublished": "2023-01-30", "url": "https://questionsmedicales.fr/article/36715786", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10103-023-03709-1" } }, { "@type": "ScholarlyArticle", "name": "Risk factors for visual field progression in newly diagnosed exfoliation glaucoma patients in Sweden.", "datePublished": "2022-06-24", "url": "https://questionsmedicales.fr/article/35750795", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-14962-9" } }, { "@type": "ScholarlyArticle", "name": "Fuzzy clustering of 24-2 visual field patterns can detect glaucoma progression.", "datePublished": "2024-09-04", "url": "https://questionsmedicales.fr/article/39231172", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pone.0309011" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Régions géographiques", "item": "https://questionsmedicales.fr/mesh/D005842" }, { "@type": "ListItem", "position": 3, "name": "Villes", "item": "https://questionsmedicales.fr/mesh/D002947" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Villes - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Villes", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Villes", "description": "Comment évaluer l'impact de la pollution urbaine sur la santé ?\nQuels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?\nComment identifier les zones à risque sanitaire en ville ?\nQuels indicateurs de santé sont pertinents en milieu urbain ?\nComment évaluer l'accès aux soins en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=5#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Villes", "description": "Quels symptômes sont liés à la pollution de l'air ?\nComment la vie urbaine affecte-t-elle la santé mentale ?\nQuels symptômes sont associés à la chaleur urbaine ?\nQuels signes indiquent une mauvaise qualité de l'eau en ville ?\nQuels symptômes sont liés à l'isolement social en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=5#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Villes", "description": "Comment prévenir les maladies liées à la pollution en ville ?\nQuelles mesures peuvent réduire le stress urbain ?\nComment améliorer la qualité de l'eau en milieu urbain ?\nQuelles stratégies aident à prévenir les coups de chaleur ?\nComment favoriser la santé mentale en milieu urbain ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=5#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Villes", "description": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?\nComment traiter les effets de la chaleur extrême en ville ?\nQuels traitements sont disponibles pour le stress urbain ?\nComment traiter les maladies liées à l'eau contaminée ?\nQuels traitements sont recommandés pour l'anxiété urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=5#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Villes", "description": "Quelles complications peuvent survenir à cause de la pollution ?\nQuels risques de santé sont liés à l'isolement social ?\nQuelles complications peuvent résulter de la chaleur extrême ?\nComment la qualité de l'eau affecte-t-elle la santé ?\nQuelles complications sont liées à la vie urbaine ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=5#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Villes", "description": "Quels facteurs de risque sont associés à la pollution urbaine ?\nComment le stress urbain influence-t-il la santé ?\nQuels sont les risques liés à la chaleur en milieu urbain ?\nQuels facteurs augmentent le risque de maladies infectieuses en ville ?\nQuels comportements augmentent le risque de problèmes de santé en ville ?", "url": "https://questionsmedicales.fr/mesh/D002947?mesh_terms=Visual+Field+Tests&page=5#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'impact de la pollution urbaine sur la santé ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'impact se mesure par des études épidémiologiques et des indicateurs de santé." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour diagnostiquer les maladies liées aux villes ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de laboratoire, des examens cliniques et des enquêtes de santé sont utilisés." } }, { "@type": "Question", "name": "Comment identifier les zones à risque sanitaire en ville ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "L'analyse géospatiale et les données de santé publique aident à identifier ces zones." } }, { "@type": "Question", "name": "Quels indicateurs de santé sont pertinents en milieu urbain ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les taux de maladies respiratoires, cardiovasculaires et d'obésité sont des indicateurs clés." } }, { "@type": "Question", "name": "Comment évaluer l'accès aux soins en ville ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'accès se mesure par la distance aux établissements de santé et la disponibilité des services." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la pollution de l'air ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent toux, essoufflement, irritation des yeux et fatigue." } }, { "@type": "Question", "name": "Comment la vie urbaine affecte-t-elle la santé mentale ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'anxiété et la dépression sont souvent exacerbés par la vie urbaine." } }, { "@type": "Question", "name": "Quels symptômes sont associés à la chaleur urbaine ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent déshydratation, épuisement et coups de chaleur." } }, { "@type": "Question", "name": "Quels signes indiquent une mauvaise qualité de l'eau en ville ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des signes incluent des maladies gastro-intestinales et des éruptions cutanées." } }, { "@type": "Question", "name": "Quels symptômes sont liés à l'isolement social en ville ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des symptômes de dépression et d'anxiété." } }, { "@type": "Question", "name": "Comment prévenir les maladies liées à la pollution en ville ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des politiques de réduction de la pollution et des campagnes de sensibilisation sont essentielles." } }, { "@type": "Question", "name": "Quelles mesures peuvent réduire le stress urbain ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Promouvoir des espaces verts et des activités communautaires aide à réduire le stress." } }, { "@type": "Question", "name": "Comment améliorer la qualité de l'eau en milieu urbain ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des systèmes de filtration et des contrôles réguliers de la qualité de l'eau sont nécessaires." } }, { "@type": "Question", "name": "Quelles stratégies aident à prévenir les coups de chaleur ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Éduquer sur l'hydratation et l'ombre, et créer des refuges frais sont des stratégies clés." } }, { "@type": "Question", "name": "Comment favoriser la santé mentale en milieu urbain ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Encourager le soutien social et l'accès à des services de santé mentale est crucial." } }, { "@type": "Question", "name": "Quels traitements sont efficaces contre les maladies respiratoires urbaines ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les bronchodilatateurs, corticostéroïdes et thérapies respiratoires sont courants." } }, { "@type": "Question", "name": "Comment traiter les effets de la chaleur extrême en ville ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, le repos et, si nécessaire, des soins médicaux." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour le stress urbain ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie cognitivo-comportementale et les médicaments peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "Comment traiter les maladies liées à l'eau contaminée ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement inclut l'hydratation, des antibiotiques et des soins symptomatiques." } }, { "@type": "Question", "name": "Quels traitements sont recommandés pour l'anxiété urbaine ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les thérapies psychologiques et les médicaments anxiolytiques sont souvent prescrits." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir à cause de la pollution ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des maladies respiratoires chroniques et des cancers." } }, { "@type": "Question", "name": "Quels risques de santé sont liés à l'isolement social ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "L'isolement peut entraîner des maladies cardiovasculaires et des troubles mentaux." } }, { "@type": "Question", "name": "Quelles complications peuvent résulter de la chaleur extrême ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des coups de chaleur, des déshydratations sévères et des décès." } }, { "@type": "Question", "name": "Comment la qualité de l'eau affecte-t-elle la santé ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Une mauvaise qualité de l'eau peut entraîner des infections et des maladies gastro-intestinales." } }, { "@type": "Question", "name": "Quelles complications sont liées à la vie urbaine ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'anxiété, la dépression et des maladies chroniques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont associés à la pollution urbaine ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'industrialisation, le trafic routier et l'urbanisation rapide." } }, { "@type": "Question", "name": "Comment le stress urbain influence-t-il la santé ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Le stress peut aggraver des conditions comme l'hypertension et l'anxiété." } }, { "@type": "Question", "name": "Quels sont les risques liés à la chaleur en milieu urbain ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées et celles avec des maladies chroniques sont particulièrement à risque." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque de maladies infectieuses en ville ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "La densité de population et l'accès limité à l'eau potable augmentent les risques." } }, { "@type": "Question", "name": "Quels comportements augmentent le risque de problèmes de santé en ville ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Le tabagisme, la sédentarité et une alimentation déséquilibrée sont des comportements à risque." } } ] } ] }

Sources (10000 au total)

Association Between Longitudinal 10-2 Central Visual Field Change and the Risk of Visual Acuity Loss in Mild-to-Moderate Glaucoma.

Faster worsening of 10-2 visual field (VF) was associated with the development of visual acuity (VA) loss in mild-to-moderate glaucoma, suggesting longitudinal 10-2 VF change is associated with the ri... To examine whether longitudinal 10-2 central VF change is associated with the risk of VA loss in glaucoma.... Primary open angle glaucoma and glaucoma suspect eyes with ≥3 years and 5 visits of 10-2 VF examinations were included. Cox proportional hazard modeling with shared frailty was used to evaluate the ha... Among the 252 eyes (148 participants, mean follow-up = 5.8 y), 30 eyes (21 participants, mean follow-up = 4.9 y) developed VA loss. There was no difference in baseline VF between eyes with and without... Faster 10-2 VF MD and hemifield MS worsening are associated with the development of VA loss. Monitoring the longitudinal central 10-degree VF change may suggest that there is impending VA impairment i...

Fuzzy clustering of 24-2 visual field patterns can detect glaucoma progression.

To represent 24-2 visual field (VF) losses of individual patients using a hybrid approach of archetypal analysis (AA) and fuzzy c-means (FCM) clustering.... In this multicenter retrospective study, we classified characteristic patterns of 24-2 VF using AA and decomposed them with FCM clustering. We predicted the change in mean deviation (MD) through super... We identified 16 characteristic patterns (archetypes or ATs) of 24-2 VF from 132,938 VFs of 18,033 participants using AA. The hybrid approach using FCM revealed a lower mean squared error and greater ... A hybrid approach combining AA and FCM to analyze 24-2 VF can visualize VF tests in characteristic patterns and enhance detection of VF progression with lossless decomposition....

Predicting Visual Field Progression by Optical Coherence Tomography Angiography and Pattern Electroretinography in Glaucoma.

Reduced P50-N95 amplitude on pattern electroretinography (PERG) and the presence of microvasculature dropout (MvD) on optical coherence tomography angiography (OCT-A) at baseline were significant fact... We investigated the baseline demographics and ocular characteristics that predict future progression in glaucoma patients, including PERG and OCT-A parameters.... One Hundred forty eyes with open angle glaucoma that were prospectively enrolled and followed up for at least 3 years, and underwent at least 5 serial VF tests were included. Baseline PERG was perform... Of the 140 eyes, 107 (76.4%) were NTG and 57 (40.7%) exhibited glaucoma progression as defined by Humphrey VF GPA. The MD slopes were -0.43±1.11 dB/y in the progressors and 0.59±1.27 dB/y in the nonpr... The presence of MvD and retinal ganglion cell dysfunction by PERG at baseline, DH or central scotoma were significant factors associated with VF progression in predominantly NTG patients. These patien...

Visual field indices in children and adults with comparable retinal nerve fiber layer thickness.

To compare visual field indices in normal children and adults with similar retinal nerve fiber layer (RNFL) thickness on optical coherence tomography (OCT).... This cross-sectional study included 59 eyes of 59 normal children 6-18 years of age compared to normal adults. The children underwent visual field testing on the Humphrey Field Analyzer (HFA) and RNFL... Overall, the MD of children was significantly less than that of the normal adults despite having the same RNFL thickness (-2.42 ± 1.42 dB vs -1.61 ± 1.47 dB [P = 0.006]). When stratified by age, the d... In our study cohort, children <12 years had lower visual field indices than adults. Their visual fields may appear worse than they would for an adult with the same RNFL thickness. Normal children >12 ...

Predicting Visual Field Worsening with Longitudinal OCT Data Using a Gated Transformer Network.

To identify visual field (VF) worsening from longitudinal OCT data using a gated transformer network (GTN) and to examine how GTN performance varies for different definitions of VF worsening and diffe... Retrospective longitudinal cohort study.... A total of 4211 eyes (2666 patients) followed up at the Johns Hopkins Wilmer Eye Institute with at least 5 reliable VF results and 1 reliable OCT scan within 1 year of each reliable VF test.... For each eye, we used 3 trend-based methods (mean deviation [MD] slope, VF index slope, and pointwise linear regression) and 3 event-based methods (Guided Progression Analysis, Collaborative Initial G... Area under the receiver operating characteristic curve (AUC).... The M6 labeled 63 eyes (1.50%) as worsening. The GTN achieved an AUC of 0.97 (95% confidence interval, 0.88-1.00) when trained with M6. Gated transformer networks trained and optimized with the other ... Gated transformer network models trained with OCT data may be used to identify VF worsening. After further validation, implementing such models in clinical practice may allow us to track functional wo... Proprietary or commercial disclosure may be found after the references....